Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06390163
Other study ID # KA-23038
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date January 5, 2024
Est. completion date November 2024

Study information

Verified date May 2024
Source Hacettepe University
Contact Büsra Seçkinogullari Korkusuz, MSc
Phone 05442436914
Email busra.seckinogullari@hacettepe.edu.tr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this single blind randomized controlled trial is to investigate the effect of sensory-perception-motor training on cognitive functions, balance and gait in patients with Parkinson's Disease? The main questions it aims to answer are: - Does sensory-perception-motor training have an effect on balance in patients with Parkinson's Disease? - Does sensory-perception-motor training have an effect on cognitive functions in patients with Parkinson's Disease? - Does sensory-perception-motor training have an effect on gait in patients with Parkinson's Disease? Patients in the control group will be asked to continue their routine lives and return for evaluation after 8 weeks. Individuals in the control group will be followed without any additional treatment or advice. Patients in the study group will receive sensory-perceptual-motor training for 60 minutes, 3 days a week for 8 weeks, in addition to their routine lives. No additional recommendations will be given to individuals in either group.


Description:

30 patients will be included in the study. Patients who agree to participate in the study will be divided into two groups, study and control groups, by using a table of random numbers, ensuring that there are equal numbers of patients in each group. Demographic and clinical information of all patients participating in the study will be recorded. Montreal Cognitive Assessment Test and Modified Hoehn Yahr Staging Scale scores of all participants will be recorded by the neurologist and eligible patients will be included in the study. Evaluations to be applied to the groups within the scope of the study: Unified Parkinson's Disease Rating Scale Part 3 , Static posturography measurement, Functional Reaching Test , Dynamic Gait Index , Rapid Mild Cognitive Impairment Screening, Stroop Test, Symbol Digit Modalities Test , Clock Drawing Test. Assessments will be made during the patients' "on" period (approximately 60 minutes after medication intake). On the first day of the study, demographic information will be recorded in both groups and the patients participating in the study will be randomized. After randomization, patients in the control group will be asked to continue their routine lives and return for evaluation after 8 weeks. Individuals in the control group will be followed without any additional treatment or advice. Patients in the study group will receive sensory-perceptual-motor training for 60 minutes, 3 days a week for 8 weeks, in addition to their routine lives. No additional recommendations will be given to individuals in either group. Patients will be excluded from the study if they participate in any physiotherapy and rehabilitation program during the study. Patients in the study group will be evaluated 3 times in total, at the beginning of the study, at the end of the study (in the 8th week) and 4 weeks after the end of the study (in the 12th week), and patients in the control group will be evaluated 2 times in total, at the beginning of the study and in the 8th week.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date November 2024
Est. primary completion date September 2024
Accepts healthy volunteers No
Gender All
Age group 45 Years to 75 Years
Eligibility Inclusion Criteria: - Being diagnosed with idiopathic Parkinson's disease - Being between the ages of 45-75 - Being between stage 2-3 according to the Modified Hoehn-Yahr Staging Scale - Having a score > 21 on the Montreal Cognitive Assessment Scale - Being literate in Turkish - No drug or dose changes throughout the study. - Not having participated in any physiotherapy or rehabilitation program in the last 6 months. - Volunteering to participate in the study Exclusion Criteria: - Presence of other neurological diseases - Presence of vision problems (that cannot be compensated with the correct lens) or vestibular disorders that may affect balance, other than symptoms related to Parkinson's disease. - Serious comorbidities that affect balance and gait or cannot be controlled with life-threatening medication (Diabetes, Hypertension, Cardiopulmonary diseases) - Long-term corticosteroid use - Presence of orthopedic and systemic diseases that may affect participation in exercise

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Sensory-Motor Integration Training
An exercise chain consisting of motor tasks, sensory stimuli and cognitive tasks will be created. Each session will include at least 3 motor tasks, 3 sensory stimuli and 3 cognitive tasks selected according to the patient's condition.

Locations

Country Name City State
Turkey Hacettepe University Ankara

Sponsors (1)

Lead Sponsor Collaborator
Hacettepe University

Country where clinical trial is conducted

Turkey, 

References & Publications (2)

Gandolfi M, Munari D, Geroin C, Gajofatto A, Benedetti MD, Midiri A, Carla F, Picelli A, Waldner A, Smania N. Sensory integration balance training in patients with multiple sclerosis: A randomized, controlled trial. Mult Scler. 2015 Oct;21(11):1453-62. doi: 10.1177/1352458514562438. Epub 2015 Jan 12. — View Citation

Taghizadeh G, Azad A, Kashefi S, Fallah S, Daneshjoo F. The effect of sensory-motor training on hand and upper extremity sensory and motor function in patients with idiopathic Parkinson disease. J Hand Ther. 2018 Oct-Dec;31(4):486-493. doi: 10.1016/j.jht.2017.08.001. Epub 2017 Nov 14. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Static Posturography It measures postural stability while standing statically and dynamically. The device has a computer-connected force platform that measures the vertical forces applied on the patients' feet (center of pressure/COG) to measure the position of the center of gravity and postural control. Baseline and week 8
Primary Modified Dynamic Gait Index Index is used to evaluate and document the ability to respond to changing task demands during gait. An increase in the score indicates that the patient's walking ability is better. Baseline and week 8
Primary Functional Reach Test It is used to evaluate dynamic balance and anteroposterior stability. In the standing position, the arm is lifted 90° upwards and stretched forward as much as possible, without losing contact with the feet. Initially, the projection of the acromion and the 3rd metacarpal bone on the wall is marked. At the final point reached after reaching forward, the projection of the 3rd metacarpal bone on the wall is marked and the difference is calculated. In elderly individuals, there is a risk of falling if the reach distance is less than 25.4 cm, and there is a risk of serious falling if it is less than 15 cm. Baseline and week 8
Primary Rapid Cognitive Screen It consists of 6 subtests: orientation, registration, clock drawing, delayed recall, verbal fluency and logical memory. This has a high degree of sensitivity in detecting cognitive impairment. It is also quick to apply, taking 3 to 5 minutes. There are cutoff points that are adjusted for factors such as age and education level. The total score is 100, and a score below 62 points indicates cognitive impairment. Baseline and week 8
Primary Symbol Digit Modalities Test It is a test frequently used in clinics because it evaluates attention, visuo-spatial information processing speed and working memory. Test is based on matching meaningless geometric shapes with certain numbers. The first 10 symbols are considered trials. Then the test starts and the person gets points for the correct marking he makes within 90 seconds. The maximum score is 60. Turkish Standardization of the test battery containing the relevant test was made and permission was obtained from the relevant authors Baseline and week 8
Primary Stroop Test The Stroop Test, which also measures the ability to change perceptual setup and response under disruptive influence, information processing speed and attention (especially selective attention).Increasing time and error indicates lower cognitive level. Baseline and week 8
Primary Clock Drawing Test Clock drawing test is an easy, quickly applicable, paper-and-pencil test with high validity and reliability used to evaluate visual-motor functions, planning, sequencing and abstract thinking skills. The Shulmann method will be used for scoring and this method evaluates out of a total of 5 points. An increase in the score indicates a better cognitive level. Baseline and week 8
Primary Movement Disorders Society Unified Parkinson's Disease Rating Scale - Part 3 It is the revised form developed in 1980, by the Movement Disorders Association in 2008. It is a revised version that will eliminate the uncertainties present in scale and include current scientific developments. The number of questions, which was 42 in scale, was increased to 50 , and questions with yes/no options were removed because they caused structural inconsistency, and all questions were scored between 0 and 4. In our study, only the 3rd Part, which includes the Motor examination, will be used. Baseline and week 8
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05103618 - Effect of Meditation and Controls and Subjects With Parkinson's Disease on Brain Activity Measured by fMRI With FDOPA Phase 2
Completed NCT03700684 - Voice Treatment for Parkinson's Disease N/A
Completed NCT04202757 - Intravenous Plasma Treatment for Parkinson's Disease Early Phase 1
Completed NCT05027620 - Feasibility of Motor-cognitive Home Training for Parkinson's Disease Using eHealth Technology N/A
Completed NCT03652363 - GDNF in ideopathicParkinsons Disease Phase 2
Recruiting NCT02960464 - tDCS for Treatment of Depression in Parkinson's Disease N/A
Completed NCT05699161 - Adipose-derived Stromal Vascular Fraction Cells to Treat Parkinson Phase 1/Phase 2
Completed NCT03944785 - Clinical Outcome Assessment of Parkinson's Disease Patients Treated With XADAGO (Safinamide)
Completed NCT01227265 - Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037) Phase 3
Terminated NCT01215227 - An Active-Controlled Extension Study to NCT01155466 [P04938] and NCT01227265 [P07037] (P06153) Phase 3
Withdrawn NCT05832775 - Study to Assess the Safety of MRx0029 or MRx0005 Compared to Placebo, in People With Parkinson's Phase 1
Active, not recruiting NCT02780895 - Parkinsonian Brain Repair Using Human Stem Cells Phase 1
Recruiting NCT01860794 - Evaluation of Safety and Tolerability of Fetal Mesencephalic Dopamine Neuronal Precursor Cells for Parkinson's Disease Phase 1/Phase 2
Completed NCT02373072 - A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 in Subjects With Idiopathic Parkinson's Disease Phase 1
Terminated NCT02393027 - Quantification of Dopamine Active Transporter (DAT) in Humans: Validation of a New Radiophamaceutical, the [18F] LBT-999 Early Phase 1
Completed NCT02445651 - Physiological Effects of Nutritional Support in Patients With Parkinson's Disease N/A
Completed NCT00437125 - Study on the Tolerability of Duloxetine in Depressed Patients With Parkinson's Disease Phase 4
Completed NCT02723396 - Sleep, Awake & Move - Part I
Completed NCT00599339 - Transdermal Rotigotine User Surveillance Study
Suspended NCT05471609 - Sustained Release Oral Formulation for Treatment of Parkinson's Disease Early Phase 1